Evgen Pharma Share Discussion Threads

[toffeeman] 28/5/2020 09:11

can't be andymunchkin is so much more eloquent :)

[lionheart69uk] 28/5/2020 08:50

Are you related to andymunchkin, who is trolling the AVCT thread?

[moneymunch] 28/5/2020 08:47

Lol...bunch of saps, sad bitter twisted and clueless...ha ha ha.... ;-)

[bumpa33] 28/5/2020 08:25

Quite the ‘fan club’ you have there mm....!?

[moneymunch] 27/5/2020 22:18

I'm not Welsh and I've never been to Cardiff......but......:-)))))

[moneymunch] 27/5/2020 21:30

Ps Ukog from 1p to double figures, plenty made plenty...MTFB 0.15p to 0.75p and then again from 0.31p to 1.49p...Ker-Ching!!! :-)

Pps and I love to copy and paste research and relevant information to highlight prospects and potential of shares i'm invested....it's the best way to learn about what you're invested and the best way to learn about the sector the company operates, much better than following sheep like and then crying like a baby when you've bought at the top and it don't work out...take it like a man ( or woman for that matter ) instead of blaming others for your incompetence and pathetic nature...ho ho ho :-)

[moneymunch] 27/5/2020 20:42

Jeez, now lionfart has turned up...
Do some research you clueless numptie...infact click on my name and see what I've been posting for the last few weeks and if you don't like it , then F' Off to wherever you came from you sad b'stard troll, otherwise buy some EVG for potential Transformational funding news, along with news of new CEO , or JV etc etc etc....Gla Holders....Fingers crossed for a stellar Rns!!!! ;-)

[peterm10] 27/5/2020 20:27

Feels like a bit of ramping on the board at the moment however some decent new research posted amongst some older articles. Think if you are in Evgeb the risks and also the upside are pretty apparent

[lionheart69uk] 27/5/2020 19:36

I recall moneymunch blatantly ramping MTFB until 15th May when he obviously gave up the ghost, the share price having since fallen drastically. He now ramps EVG and will most likely desert the sinking ship once the price falls again. A shorter perhaps?

[toffeeman] 27/5/2020 13:00

A ramper on this board? you must be joking :) :)

[chuffer2] 27/5/2020 12:56

What's need here is a good old fashioned ramper.
You know the sort, a classic pumper and dumper.
Can anyone think of anybody??????
Lol

[bumpa33] 27/5/2020 11:30

I think that is probably the likely case here - funding deal plus an exchange for a % of the company at an agreed level - which as stated before and judging by prices seen seems to be around the 13 level, where we are right now.

[moneymunch] 27/5/2020 11:20

Could be funding in lieu of a share %, whereby all the Major Shareholders have trimmed their holdings to accommodate a commercial JV, without dilution , and disclosure will be made on deal completion!!!??? Hopefully not too much longer to find out....Fingers crossed for a stellar Rns. Gla :-)

[mesquida] 27/5/2020 08:45

Another day without an RNS holdings disclosure, all very odd.

[moneymunch] 26/5/2020 18:52

Should be interesting to see who the new CEO will be. Gla ;-)

[moneymunch] 26/5/2020 18:47

MANAGEMENT

It is a reflection of the very significant potential of Evgen Pharma’s technology that the company has been able to attract a high calibre commercial, scientific and advisory team.

SALLY ROSS, CLINICAL DEVELOPMENT OFFICER

Sally has over 18 years of experience working across pre-clinical and clinical settings in academia, pharma and CROs.  Sally held many different roles at AstraZeneca, starting off as a translational Scientist working on Iressa and then moved into more clinical roles as a Global Project/Programme Manager in the Oncology and Infection Therapeutic Areas, and subsequently as a Principal Medical Scientist in both early and late clinical development. Upon leaving AstraZeneca Sally worked for a large mid-sized contract research organisation as Director of Project Management.

CONSULTANTS DR THOMAS MORRIS – MEDICAL ADVISOR

Tom is a physician who has worked in pharmaceutical medicine and drug development for over 20 years with much of this time specialising in oncology. After several years working in clinical medicine, he joined firstly Medeval Ltd (University of Manchester) and then AstraZeneca, where he has held a number of global R&D roles. Most recently these included Senior Medical Director and Executive Director Clinical Programs. He has overseen several global drug development programs, interacting with leading external medical and scientific experts, academic groups and regulatory agencies.

[moneymunch] 26/5/2020 18:24

Another strong Astazeneca connection. Gla ;-)

DR ALAN BARGE, NON-EXECUTIVE DIRECTOR

Alan is the former chief medical officer of Singapore-based ASLAN Pharmaceuticals PTE. Up until 2011, he was vice-president and head of oncology & infection at AstraZeneca, a role in which he was responsible for the overall strategy in oncology and infection from drug discovery to proof-of-concept. He was also chairman of AstraZeneca’s Therapy Area Portfolio Team and accountable for the design and delivery of all projects, including budgetary oversight. Prior to his career at AstraZeneca, Alan was European and global medical director for Amgen Inc.

[moneymunch] 26/5/2020 11:38

Not if it's to do with JV or some sort of partnership investment etc imho, and I'm fairly certain that we'll all find out soon enough. Gl :-)

[mesquida] 26/5/2020 10:44

Moneymunch, I think that you will find that the 3% disclosure rule over-rides such considerations.

[moneymunch] 26/5/2020 10:11

If the massive share trades are related to ongoing material developments, then no disclosure is requierd until negotiations are completed. Gl; ;-)

"In summary, issuers must notify without delay major new developments that may affect their business if the development may lead to a substantial share price movement. Issuers must also notify without delay information concerning a change in financial condition, performance or expectation of performance if the change would be likely to lead to a substantial share price movement.

There are exclusions from these notification requirements relating to impending developments and matters in the course of negotiation, such as acquisitions or disposals. There is also a power for the UKLA to grant a dispensation from these requirements where the disclosure to the public of information might prejudice the company's legitimate interests"